Evidence map›Paper›PMID 36876914›Full record

ArticleeLife2023

Transferred mitochondria accumulate reactive oxygen species, promoting proliferation.

Chelsea U Kidwell, Joseph R Casalini, Soorya Pradeep, Sandra D Scherer, Daniel Greiner, Defne Bayik, Dionysios C Watson, Gregory S Olson, Justin D Lathia, Jarrod S Johnson and 4 more

Full text read
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chelsea U Kidwell *Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, United States.ORCID 0000-0003-4269-2503
Joseph R Casalini *Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, United States.ORCID 0000-0002-3515-3248
Soorya PradeepDepartment of Chemical Engineering, University of Utah, Salt Lake City, United States.
Sandra D SchererDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, United States.ORCID 0000-0002-7943-8595
Daniel GreinerDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, United States.
Defne BayikDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Case Western Reserve University, Cleveland, United States.
Dionysios C WatsonDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Case Western Reserve University, Cleveland, United States.
Gregory S OlsonMedical Scientist Training Program, University of Washington, Seattle, United States.
Justin D LathiaDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Case Western Reserve University, Cleveland, United States.
Jarrod S JohnsonDivision of Microbiology & Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, United States.ORCID 0000-0001-7355-5240
Jared RutterDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, United States.ORCID 0000-0002-2710-9765
Alana L WelmDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, United States.
Thomas A ZangleDepartment of Chemical Engineering, University of Utah, Salt Lake City, United States.
Minna Roh-JohnsonDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, United States.ORCID 0000-0003-3961-4547

Funding

Tolinapant efficacy in a subset of triple negative breast cancersU54CA224076 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Michael T. Lewis · 2017 to 2026
$13.5M
Mitochondrial Biochemistry: From Mechanisms to DiseaseR35GM131854 · NIGMS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 2019 to 2026
$3.3M
NRSA Training CoreTL1TR002549 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI HARDING, CLIFFORD V · 2018 to 2022
$2.9M
Mitochondrial lateral transfer during metastasisR37CA247994 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Minna Roh · 2021 to 2026
$2.4M
Cell Biological Mechanisms of Melanoma Cell Motility In VivoR00CA190836 · NCI · UNIVERSITY OF UTAH · PI ROH, MINNA · 2018 to 2020
$954k
Role of myeloid-derived suppressor cells in local and systemic immunosuppression in glioblastomaK99CA248611 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI BAYIK WATSON, DEFNE · 2021 to 2022
$241k
Identifying the Mechanisms Governing Mena-Induced Tumor Cell DisseminationF32CA159663 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI ROH, MINNA · 2011 to 2013
$139k
Investigating macrophage-to-tumor mitochondrial transferF31CA250317 · NCI · UNIVERSITY OF UTAH · PI CASALINI, JOSEPH RAYMOND · 2021 to 2023
$100k
NCATS NIH HHS TL1 TR002549NCI NIH HHS F31 CA250317NCI NIH HHS F32 CA159663NCI NIH HHS K99 CA248611NCI NIH HHS R00 CA190836NCI NIH HHS R37 CA247994NCI NIH HHS U54 CA224076NIGMS NIH HHS R35 GM131854NIH HHS F31CA250317NIH HHS K99 CA248611NIH HHS R00CA190836NIH HHS R37CA247994NIH HHS TL1 TR002549NIH HHS U54CA224076
6 · The paper itself

Abstract

Recent studies reveal that lateral mitochondrial transfer, the movement of mitochondria from one cell to another, can affect cellular and tissue homeostasis. Most of what we know about mitochondrial transfer stems from bulk cell studies and have led to the paradigm that functional transferred mitochondria restore bioenergetics and revitalize cellular functions to recipient cells with damaged or non-functional mitochondrial networks. However, we show that mitochondrial transfer also occurs between cells with functioning endogenous mitochondrial networks, but the mechanisms underlying how transferred mitochondria can promote such sustained behavioral reprogramming remain unclear. We report that unexpectedly, transferred macrophage mitochondria are dysfunctional and accumulate reactive oxygen species in recipient cancer cells. We further discovered that reactive oxygen species accumulation activates ERK signaling, promoting cancer cell proliferation. Pro-tumorigenic macrophages exhibit fragmented mitochondrial networks, leading to higher rates of mitochondrial transfer to cancer cells. Finally, we observe that macrophage mitochondrial transfer promotes tumor cell proliferation in vivo. Collectively these results indicate that transferred macrophage mitochondria activate downstream signaling pathways in a ROS-dependent manner in cancer cells, and provide a model of how sustained behavioral reprogramming can be mediated by a relatively small amount of transferred mitochondria in vitro and in vivo.

Indexed as

MitochondriaNeoplasmsCell ProliferationHumansReactive Oxygen SpeciesSignal TransductionReactive Oxygen Speciescancercancer biologycell biologycell-cell communicationcell proliferationhumanmacrophagesmitochondrial transfermousereactive oxygen species

Identifiers

PMID36876914
PMCPMC10042539

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read129
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.